Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer.

Nerlynx (neratinib) - Puma

http://www.ncbi.nlm.nih.gov/pubmed/41968987

Han Wang; Xin Hu; Yaxin Zhao; Ying Wang; Yizhou Jiang; Zhiming Shao

Apr 13, 2026